Hung joins the board with more than 25 years of leadership and management experience in the life sciences industry.
Previously, he was the founder, president, and chief executive officer of Medivation from 2004 through 2016 when it was acquired by Pfizer for approximately USD 14bn.
Medivation developed Xtandi for the treatment of metastatic and non-metastatic prostate cancer from invention to FDA approval in seven years, one of the fastest development times in biopharmaceutical history.
In 2016, Xtandi had become the world's leading prostate cancer therapy, with nearly USD 2.5bn in annual revenue.
At Medivation, Hung built a pipeline of cancer therapies addressing significant unmet needs including a potentially best-in-class poly (ADP-ribose) polymerase inhibitor (talazoparib) which was recently approved for germline BRCA-mutated, HER2-negative, locally advanced and/or metastatic breast cancer.
From April 2017 to February 2018, Dr. Hung was chief executive officer and a director of Axovant Sciences, Inc.
He received an M.D. alpha omega alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in Biology from Harvard College.
Agilvax discovers and develops targeted antibody-based therapeutics for the treatment of various cancers.
The company's lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is over expressed on many different tumor types including breast cancer, hepatocellular cancer, lung cancer, and pancreatic cancer.
Agilvax is developing AX09 initially for the treatment of metastatic triple negative breast cancer.
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
Merck finalises acquisition of Harpoon Therapeutics Inc
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA
Camurus reports Oclaiz NDA accepted by FDA for acromegaly treatment
TME Pharma plans NOX-A12 Phase 2 trial in brain cancer after FDA IND clearance